Opthalmic Lasers Clinical Trial Analysis

Summary

Global Markets Direct's "Opthalmic Lasers Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Opthalmic Lasers manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Opthalmic Lasers market categories - Opthalmic Lasers
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Opthalmic Lasers market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Opthalmic Lasers Clinical Trials
  • 2.1 Opthalmic Lasers Clinical Trial By Equipment Type
  • 2.2 Opthalmic Lasers Clinical Trials By Trial Phase and Trial Status
  • 2.3 Opthalmic Lasers Pipeline Products By Development Stage
  • 2.4 Opthalmic Lasers Pipeline Products By Therapy Area
  • 2.5 Opthalmic Lasers Pipeline Products By News Summary
  • 2.6 Opthalmic Lasers PULZAR Z1 system
    • 2.6.1 One-year results of photorefractive keratectomy and laser in situ keratomileusis for myopia using a 213 nm wavelength solid-state laser
    • 2.6.2 Results in high myopic and mixed astigmatisms with the solid state laser (213nm)
  • 2.7 Opthalmic Lasers OptiVision
    • 2.7.1 Clinical Trials On Optivision Laser Reversal Of Presbyopia
  • 2.8 Opthalmic Lasers OT-134 laser device
    • 2.8.1 The Successful Completion Of An Initial Human Clinical Study On Ot-134 Device
    • 2.8.2 A Study On A Novel Laser-Based Therapy For The Treatment Of Glaucoma Completed
  • 2.9 Opthalmic Lasers Ellex 2RT
    • 2.9.1 A Study To Show That Ellex 2RT Is Clinically Safe And Effective
    • 2.9.2 A Clinical Study To Demonstrate Effectiveness Of Ellex 2RT To Improve And Stabilize Visual acuity
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Apr 27, 2009: Successful 12 Month Follow-Up Results Of IOPtima's Novel Laser System For The Treatment Of Glaucoma
    • 3.1.2 Apr 03, 2009: Carl Zeiss Meditec Introduces Next Generation Of Its VisuMax Femtosecond Laser
    • 3.1.3 Nov 10, 2008: Ellex Announces Six-Month Results On Retina Regeneration Therapy
    • 3.1.4 Aug 15, 2008: IRIDEX Announces FDA Clearance For New 577 nm True-Yellow Laser
    • 3.1.5 Jul 18, 2007: AMO Receives FDA Approval For Advanced CustomVue Monovision Procedure For The Treatment Of Presbyopic Myopes
    • 3.1.6 Jan 18, 2007: Carl Zeiss Meditec Receives FDA Clearance To Market VISUMAX Femtosecond Laser System
  • 3.2 Product Approvals
    • 3.2.1 Aug 15, 2008: IRIDEX Announces FDA Clearance For New 577 nm True-Yellow Laser
  • 3.3 Clinical Trials
    • 3.3.1 Apr 27, 2009: Successful 12 Month Follow-Up Results Of IOPtima's Novel Laser System For The Treatment Of Glaucoma
    • 3.3.2 Nov 10, 2008: Ellex Announces Six-Month Results On Retina Regeneration Therapy
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Opthalmic Lasers Clinical Trial By Equipment Type
  • Table 2: Opthalmic Lasers Clinical Trials By Trial Phase and Trial Status
  • Table 3: Opthalmic Lasers Pipeline Products By Development Stage
  • Table 4: Opthalmic Lasers Pipeline Products By Therapy Area
  • Table 5: Opthalmic Lasers Pipeline Products By News Summary
  • Table 6: PULZAR Z1 system - One-year results of photorefractive keratectomy and laser in situ keratomileusis for myopia using a 213 nm wavelength solid-state laser
  • Table 7: PULZAR Z1 system - Results in high myopic and mixed astigmatisms with the solid state laser (213nm)
  • Table 8: OptiVision - Clinical Trials On Optivision Laser Reversal Of Presbyopia
  • Table 9: OT-134 laser device - The Successful Completion Of An Initial Human Clinical Study On Ot-134 Device
  • Table 10: OT-134 laser device - A Study On A Novel Laser-Based Therapy For The Treatment Of Glaucoma Completed
  • Table 11: Ellex 2RT - A Study To Show That Ellex 2RT Is Clinically Safe And Effective
  • Table 12: Ellex 2RT - A Clinical Study To Demonstrate Effectiveness Of Ellex 2RT To Improve And Stabilize Visual acuity
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology